Forty-eight hours of normothermic kidney preservation applying urine recirculation

Annemarie Weissenbacher1 | Franka Messner1 | Silvia Gasteiger1 | Afschin Soleiman2 | Dietmar Öfner1 | Stefan Schneeberger1

1Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, Innsbruck, Austria
2INNPATH, Institute of Pathology, Tirol Kliniken Innsbruck, Innsbruck, Austria

Correspondence
Annemarie Weissenbacher, Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, Innsbruck, Austria.
Email: annemarie.weissenbacher@i-med.ac.at

1 | INTRODUCTION

End-stage renal disease (ESRD) is a major global health burden. It is projected that 5.4 million people will receive renal replacement therapy (RRT) by 2030 and up to approximately seven million adult people will have died due to lack of access to RRT.1 The preferable type of RRT for most ESRD patients is kidney transplantation. Due to the evident organ scarcity and the great disparity between transplantable kidneys and patients on RRT and the waiting list, access to kidney transplantation is limited. The transplant community has been working on enlarging the donor pool by recovering and transplanting more marginal organs from extended criteria and donors after circulatory death. Implementing kidney preservation technologies like hypothermic machine perfusion (HMP)2 and moving kidney viability assessment to a clinically applicable level by normothermic machine perfusion (NMP) of deceased donor kidneys3 have been relevant measures contributing to increase the supply of transplantable kidneys. In the clinical setting, kidney NMP has been applied for one to two hours before such organs have been either declined or transplanted. Short-term kidney NMP cannot improve transplant logistics and currently, no transportable stand-alone perfusion device enabling long-term preservation is commercially available.

The aim of our perfusion experiment was to preserve a discarded human kidney normothermically for up to 48 h proving the principle of urine recirculation in terms of stable perfusion hemodynamics and perfusate homeostasis according to the protocol published by Weissenbacher et al.4,5 Achieving long-term kidney preservation might be a key element required for the realization of an international or even global exchange of solid organs to allocate reconditioned and repaired organs, which are discarded otherwise, to the most suitable recipients. Besides possible treatment of the organ, preserving kidneys beyond 24 h offers potential treatment of immunologically complex recipients prior to transplantation.

2 | CASE DESCRIPTION

The human kidney graft included in this case report was retrieved for transplant but discarded at the recipient center. The perfusion was performed in the laboratory of the Organ Regeneration Center of Excellence, organLife™, Medical University of Innsbruck. Hemodynamic and biochemical perfusion parameters were analyzed. Perfusate, urine, and biopsy samples were obtained during perfusion. The study was evaluated and approved by the institutional ethics committee (EK Nr. 1216/2019).
2.1 | Preparation of kidney graft, the composition of perfusate, and perfusion set-up

The kidney arrived at the transplant center in an icebox, preserved in Custodiol® HTK (histidine-tryptophan-ketoglutarate) solution, and was placed on the LifePort kidney transporter (Organ Recovery Systems) immediately after arrival. After deemed untransplantable, the organ was taken off the HMP device and prepared for connection to the NMP circuit. For NMP, the Organ Assist Kidney Assist (XVIVO Perfusion) device was used. The renal artery was cannulated with a 10-Fr cannula. The ureter was cannulated with a T-tube to recirculate the urine. The disposable set was adapted by implementing an in-line blood gas analyzer (CDI500, Terumo Medical Corporation). Perfusate temperature was set at 37°C. Oxygenation of the circuit was facilitated by manual regulation of air (21% oxygen) and CO₂. The perfusion circuit was primed with three units of packed RBCs of the same blood group as the kidney, resuspended in 1000 ml 5% human albumin solution (Octapharma), resulting in a total perfusate volume of approximately 1800 ml; adapted from the protocol published by Weissenbacher et al.⁴ Before connecting the kidney, the perfusate was supplemented with 750 mg cefuroxime, 10 ml calcium gluconate, and 8000 IE enoxaparin, low molecular weight heparin (LMWH). For pH adjustment prior to initiation of NMP, 10 ml of sodium bicarbonate 8.4% were added to the perfusate to achieve a physiological pH level of 7.3. Immediately after perfusion start, 5 ml verapamil was administered directly into the arterial line. For glucose and electrolyte monitoring, regular blood gas analyzer measurements were performed and 5 ml of total parenteral nutrition (Nutriflex Special, containing 0.24 g/ml glucose) was administered once perfusate glucose levels dropped below 70 mg/dl.

2.2 | Kidney characteristics

A 62-year-old kidney from a male donation after brain death donor was allocated for experimental long-term NMP after being declined by all transplant centers within Eurotransplant due to a malignant neoplasm of the partner kidney. The cause of death was a cerebrovascular accident caused by a spontaneous intracerebral hematoma, last donor serum creatinine and urea were 0.9 mg/dl and 4.4 mmol/L, the last urine output was 600 ml over 6 h, history of hypertension was unknown and there was no evidence of diabetes mellitus. The kidney donor risk and profile indexes were 1.33 and 78%. Remuzzi score of the zero-biopsy was 0 (Figure 1A). Overall cold ischemia time, until NMP-start, was 27 h and 3 min including 4.5 h on the HMP device.

2.3 | Perfusion characteristics

The mean arterial pressure was fixed at 90 mm Hg right from the start of NMP and the perfusate temperature was between 36 and 37°C. The kidney was perfused for 48 h and the urine recirculated. Figure 1B–C is displaying biopsy results after 6 (medulla only) and 48 h. No glo-merular and/or tubular necrosis occurred over the 48 h NMP period according to the histological assessment of the whole kidney. Figure 2A–D shows photographs of the perfused kidney 30 min, 6, 24, and 48 h after NMP-start.

Median (IQR) pO₂ and pCO₂ levels were in the physiological range of 113.5 (6.3) and 38 (3.7) mm Hg throughout; median (IQR) pH was 7.44 (0.11). Table 1 outlines hemodynamic and metabolic function parameters. Arterial flow 30 min after NMP-start was 370 ml/min with a corresponding intrarenal resistance (IRR) of 0.25 mm Hg/ml/min. The median (IQR) arterial flow was 850.5 (79) ml/min and the median IRR was 0.11 (0.02) mm Hg/ml/min. At hour 40, the arterial flow reached 900 ml/min and the perfusion device alarmed, without interrupting NMP, as this flow level was the maximum that could be reached by the device. As a consequence, the MAP was decreased and set to 80 mm Hg and perfusion continued without any complications. Figure 1D displays arterial flow, MAP, and IRR per hour, and Figure 2E–I shows photographs of the graphical user interface at 90 min, 6, 24, 40, and 48 h after NMP-start.

Biochemistry parameters of the perfusate before NMP-start were: Hemoglobin 8.8 g/l, potassium 8.9 mmol/L, sodium 146 mmol/L, chloride 125 mmol/L, glucose 126 mg/dl, and lactate 81 mg/dl (normal range 4–14 mg/dl). Median (IQR) perfusate lactate was 88.5 (11.75) mg/dl and similar to median urine lactate with 81.5 (33.8) mg/dl over time; p = 0.2. Median (IQR) perfusate sodium and chloride were significantly higher with 153.5 (4) mmol/L and 129 (6) mmol/L compared to median urine sodium with 136.5 (24.7) mmol/L and 122 (9.5) mmol/L over time, p < 0.001 and 0.009. Median (IQR) perfusate glucose was insignificantly higher with 67.5 (36.5) mg/dl compared to median urine glucose with 48 (25.3) mg/dl during 48 h of NMP, p = 0.047. A total of 55 ml TPN was administered during 48 h of NMP, equivalent to an overall amount of 13.2 g glucose. Figure 1E illustrates the differences between sodium, chloride, glucose, and lactate in perfusate and urine per perfusion hour. Anti-Xa levels over time were 10.4 IU/ml after 1, 6.2 IU/ml after 6, 3.9 IU/ml after 24, and 2.1 IU/ml after 48 h of NMP. Hemoglobin level at the end of perfusion was 7.7 g/l and potassium 7.9 mmol/L. Free hemoglobin was rising over time from 0.06 g/dl at hour 1 after NMP-start to 0.14 g/dl at hour 48 and was the reason to terminate the perfusion. Excreted and recirculated urine volume per hour was approximately 22.5 ml until hour 48 of NMP.
This is the first report of 48 h of normothermic ex-situ kidney perfusion applying urine recirculation to enable stable perfusion hemodynamics and homeostasis. Urine recirculation was chosen in this setting as the feasibility of this technique to control perfusate volume has been successfully demonstrated in 24-h kidney NMP before. We considered that the lack of excretory kidney function, as a result of urine recirculation, would be unlikely to have any severe physiological consequences within the 48-h time frame. Comparing the ex-situ environment with an adult and anephric person requiring hemodialysis sessions three times a week, the expected urea accumulation would be insignificant and acceptable in a single-kidney-only milieu. The histology results at 48 h illustrate intact morphological tubular and glomerular structures. There were no signs of hemosiderin deposits, caused by severe hemolysis, and no thrombosis. Some areas of the kidney (Figure 1C) showed unspecific anisometric cytoplasmatic changes of the proximal tubules, which could be an effect of osmotic changes of the perfusate, with increasing sodium and chloride levels (Figure 1E), over time. More distinct tubular vacuolization was described by the Oxford group as a mannitol effect that is causing osmotic imbalance. All of their 24-h kidney biopsies, without mannitol as a supplement, showed normal preserved tubules. The main difference of the work published by the Oxford group, using a fully closed circuit with a cannulated renal vein and a soft-shell reservoir, is the open perfusion setting with the renal vein draining directly into the kidney bowl which serves as a reservoir in our case. This open setting might contribute substantially to the increasing amount of free hemoglobin when a flow of approximately 800 ml/min is considered over a full 2-day period. With the current knowledge, it is more difficult to interpret perfusate lactate in the kidney setting compared to the liver as the physiology is different and lactate itself depending on the metabolic state of the organ.

Enoxaparin was the preferred anticoagulant as it can be administered once as a bolus and due to the characteristic that low molecular weight heparin is cleared by the renal route, after primary metabolism in the liver (missing in an isolated ex-situ kidney NMP circuit), known to accumulate in patients suffering from chronic kidney disease. Enoxaparin offers, therefore, the possibility to measure anti-factor Xa activity over time, serving as a potential biomarker.

In summary, it is feasible to perfuse and preserve a human kidney ex-situ normothermically for 48 h. Currently, it is unknown whether a more extended...
criteria donor organ could be preserved effectively for 48 h and this is an important question to answer, as such marginal organs are likely to be the ones requiring extended preservation periods to enable therapeutic interventions in future. Furthermore, more experimental work needs to be dedicated to define the most optimal and physiological perfusate composition to implement long-term ex-situ kidney preservation in the clinical routine.

**CONFLICT OF INTEREST**
The authors declare that they have no conflicts of interest with the contents of this article.

**AUTHOR CONTRIBUTIONS**
Annemarie Weissenbacher: concept and design of perfusion set-up and performing the organ perfusion, data collection and analysis, drafting the article; Franka Messner, Silvia Gasteiger: supporting the perfusion and

---

**TABLE 1** Hemodynamic and metabolic parameters

|                         | Hour 1 | Hour 6 | Hour 12 | Hour 18 | Hour 24 | Hour 30 | Hour 36 | Hour 42 | Hour 48 |
|-------------------------|--------|--------|---------|---------|---------|---------|---------|---------|---------|
| Arterial pressure in mm Hg | 90     | 90     | 90      | 90      | 90      | 90      | 90      | 90      | 80      |
| Arterial flow in ml/min   | 370    | 762    | 786     | 815     | 853     | 870     | 897     | 858     | 874     |
| IRR in ml/min/mm Hg       | 0.24   | 0.12   | 0.11    | 0.11    | 0.11    | 0.1     | 0.1     | 0.1     | 0.1     |
| pH                       | 7.47   | 7.39   | 7.35    | 7.45    | 7.32    | 7.44    | 7.42    | 7.42    | 7.45    |
| Perfusate lactate level in mg/dl | 83 | 89    | 83      | 87      | 88      | 90      | 100     | 106     | 104     |
| Urine lactate level in mg/dl | 101   | 72     | 63      | 65      | 68      | 85      | 90      | 106     | 104     |
| Perfusate glucose level in mg/dl | 110 | 96     | 68      | 67      | 125     | 47      | 30      | 66      | 64      |
| Urine glucose level in mg/dl  | 110   | 43     | 46      | 42      | 75      | 40      | 70      | 63      | 60      |
| Perfusate sodium in mmol/L  | 145    | 150    | 152     | 154     | 154     | 153     | 155     | 154     | 154     |
| Urine sodium in mmol/L     | 137    | 103    | 126     | 133     | 136     | 139     | 141     | 147     | 150     |
| Perfusate chloride in mmol/L | 125   | 124    | 125     | 129     | 129     | 131     | 131     | 132     | 132     |
| Urine chloride in mmol/L   | 122    | 99     | 119     | 121     | 122     | 124     | 125     | 127     | 127     |
data collection; Afschin Soleiman: histological analyses; Dietmar Öfner, Stefan Schneeberger: revision of the article.

ORCID

Annemarie Weissenbacher © https://orcid.org/0000-0002-0582-1815

REFERENCES

1. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020 Feb 29;395(10225):709–33.

2. Moers C, Smits JM, Maathuis M-HJ, Treckmann J, van Gelder F, Napieralski BP, et al. Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med. 2009;360(1):7–19.

3. Nicholson ML, Hosgood SA. Renal transplantation after ex vivo normothermic perfusion: the first clinical study. Am J Transplant. 2013 May;13(5):1246–52.

4. Weissenbacher A, Lo Faro L, Boubriak O, Soares MF, Roberts IS, Hunter JP, et al. Twenty-four-hour normothermic perfusion of discarded human kidneys with urine recirculation. Am J Transplant. 2019;19:178–92.

5. Weissenbacher A, Huang H, Surik T, Lo Faro ML, Ploeg RJ, Coussios CC, et al. Urine recirculation prolongs normothermic kidney perfusion via more optimal metabolic homeostasis—a proteomics study. Am J Transplant. 2021 May;21(5):1740–53.